Exousia Bio, Inc.

Exousia Bio (LMMY) shows no detected cyber incidents or material red-flag 8-K filings in the past 90 days, presenting a clean recent operational surface. However, a compressed monitoring window provides limited visibility into structural risks common in early-stage biotech: equity dilution patterns, financing runway, and cash burn trajectory remain unexamined. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scoring, maps financing history and burn rates, and flags AI-detected anomalies in management disclosures and capital structure. The full $49 Report adds quantified dilution risk, 12-month red-flag context, financing sustainability analysis, and AI-detected capital structure signals.